Down regulation of interferon gamma and up regulation of interleukin-10 by ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis (PSC).

被引：0
|
作者：
Mitchell, SA
Bansi, D
Christie, J
Fleming, KA
Chapman, RW
机构：
[1] JOHN RADCLIFFE HOSP,DEPT GASTROENTEROL,OXFORD OX3 9DU,ENGLAND
[2] JOHN RADCLIFFE HOSP,NUFFIELD DEPT PATHOL,OXFORD OX3 9DU,ENGLAND
来源：
HEPATOLOGY | 1997年 / 26卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：814 / 814
页数：1
相关论文
共 50 条
  • [21] COX-2 down-regulation by ursodeoxycholic acid is chemopreventive in ulcerative colitis patients with primary sclerosing cholangitis.
    Chang, A
    Agoff, SN
    Raaka, S
    Taylor, SL
    Brentall, TA
    Tung, BY
    Emond, MJ
    Haggitt, RC
    Rabinovitch, PS
    Bronner, MP
    MODERN PATHOLOGY, 2001, 14 (01) : 82A - 82A
  • [22] COX-2 down-regulation by ursodeoxycholic acid is chemopreventive in ulcerative colitis patients with primary sclerosing cholangitis.
    Chang, A
    Agoff, SN
    Raaka, S
    Taylor, SL
    Brentall, TA
    Tung, BY
    Emond, MJ
    Haggitt, RC
    Rabinovitch, PS
    Bronner, MP
    LABORATORY INVESTIGATION, 2001, 81 (01) : 82A - 82A
  • [23] Ursodeoxycholic acid in the treatment of primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) in pregnancy.
    Holtmeier, J
    Leuschner, M
    Holtmeier, W
    Stiehl, A
    Klein, R
    Leuschner, U
    HEPATOLOGY, 2002, 36 (04) : 491A - 491A
  • [24] SINGLE-DOSE OR MULTIPLE DOSES OF URSODEOXYCHOLIC ACID (UDCA) ARE EQUALLY EFFECTIVE IN THE TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS (PSC) AND PRIMARY BILIARY-CIRRHOSIS (PBC)
    VANDEMEEBERG, PC
    WOLFHAGEN, FHJ
    VANERPECUM, KJ
    SALEMANS, JMJI
    SCHALM, SW
    VANBERGEHENEGOUWEN, GP
    GASTROENTEROLOGY, 1995, 108 (04) : A1191 - A1191
  • [25] INTERLEUKIN-10 AND INTERFERON-GAMMA REGULATION OF EXPERIMENTAL TRYPANOSOMA-CRUZI INFECTION
    SILVA, JS
    MORRISSEY, PJ
    GRABSTEIN, KH
    MOHLER, KM
    ANDERSON, D
    REED, SG
    JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 175 (01): : 169 - 174
  • [26] Ursodeoxycholic acid (UDCA) for primary sclerosing cholangitis (PSC): Results of a 2-year randomized controlled trial evaluating single versus multiple daily doses
    vanHoogstraten, HJF
    vandeMeeberg, PC
    Wolfhagen, FHJ
    Kuiper, H
    Hop, WCJ
    vanBergeHenegouwen, GP
    Schalm, SW
    vanBuuren, HR
    HEPATOLOGY, 1997, 26 (04) : 1089 - 1089
  • [27] INITIAL RESULTS OF THE WUPPSC STUDY - PROSPECTIVE MULTICENTER WITHDRAWAL OF URSODEOXYCHOLIC ACID IN PEDIATRIC PRIMARY SCLEROSING CHOLANGITIS (PSC)
    Black, Dennis D.
    Mack, Cara L.
    Kerkar, Nanda
    Miloh, Tamir
    Sundaram, Shikha S.
    Anand, Ravinder
    Gupta, Ashutosh
    Alonso, Estella
    Arnon, Ronen
    Bulut, Pinar
    Karpen, Saul J.
    Lin, Chuan-Hao
    Rosenthal, Philip
    Ryan, Matthew
    Squires, Robert H.
    Valentino, Pamela L.
    Shneider, Benjamin L.
    GASTROENTEROLOGY, 2018, 154 (06) : S1209 - S1209
  • [28] High dose ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis (PSC): Results after two years of a randomised double-blind, placebo-controlled trial.
    Mitchell, SA
    Bansi, D
    Hunt, N
    Christie, J
    Fleming, K
    Chapman, R
    GUT, 1997, 40 : TH115 - TH115
  • [29] High dose ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis (PSC): Results after two years of a randomised double-blind, placebo-controlled trial.
    Mitchell, S
    Bansi, D
    Hunt, N
    Christie, J
    Fleming, K
    Chapman, R
    GASTROENTEROLOGY, 1997, 112 (04) : A1335 - A1335
  • [30] Primary sclerosing cholangitis (PSC): Standard liver function tests during long term treatment with ursodeoxycholic acid (UDCA) and value of serial quantitative liver function tests.
    vonSchonfeld, J
    Mahl, M
    Zotz, R
    Beste, M
    Breuer, N
    Goebell, H
    GASTROENTEROLOGY, 1996, 110 (04) : A1355 - A1355
12345